Turn Therapeutics Inc.
TTRXHealthcare|Biotechnology|US
$9.48
+0.54 (+6.04%)
DCF Value
$0.18
Cash / Share
$0.35
Financials
Financial Snapshot
Market Cap
$287.9M
Enterprise Value
$283.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$8.4M
Cash & Investments
$10.3M
Net Cash
$4.2M
Free Cash Flow (TTM)
-$4.3M
Operating CF (TTM)
-$4.3M
Debt/Equity
8.91
Cash Runway & Burn Rate
Cash on Hand
$10.3M
Quarterly Burn
$1.1M
Monthly Burn
$360.1K
Est. Runway
~9.5 quarters
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $2.1M | $1.2M | $872.6K | $5.1M | $10.3M | |
| Operating Cash Flow | -$1.2M | -$1.4M | -$1.4M | -$2.6M | -$4.3M | |
| Free Cash Flow | -$1.2M | -$1.4M | -$1.5M | -$2.7M | -$4.3M | |
| Capital Expenditure | $0.00 | -$44.3K | -$99.5K | -$153.0K | -$2.00 | |
| Financing Cash Flow | $350.0K | $500.0K | $1.2M | $6.9M | $11.6M |
R&D Spending
R&D (TTM)
$778.1K
R&D Intensity
—
R&D Growth vs Prior
+193.0%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $7.5K | $246.0K | $265.6K | $778.1K | |
| SG&A | $4.2M | $2.3M | $1.6M | $5.6M | $6.1M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $52.7K | $0.00 | $0.00 | $0.00 | $56.8K | |
| Gross Profit | -$52.7K | $0.00 | $0.00 | $0.00 | -$56.8K | |
| R&D | $0.00 | $7.5K | $246.0K | $265.6K | $778.1K | |
| SG&A | $4.2M | $2.3M | $1.6M | $5.6M | $6.1M | |
| Operating Income | -$4.2M | -$2.3M | -$1.8M | -$5.9M | -$7.0M | |
| Interest Expense | $85.4K | $0.00 | $0.00 | $0.00 | $241.4K | |
| Pretax Income | -$4.3M | -$2.3M | -$1.8M | -$3.2M | -$8.4M | |
| Net Income | -$4.3M | -$2.3M | -$1.8M | -$3.2M | -$8.4M | |
| EPS (Diluted) | -0.33 | -0.17 | -0.13 | -0.23 | -0.29 | |
| EBITDA | -$4.2M | -$2.2M | -$1.7M | -$3.1M | -$4.2M | |
| Shares Out. (M) | 13.18 | 13.25 | 13.42 | 13.74 | 29.79 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $1.2M | $872.6K | $5.1M | $10.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.1M | $1.2M | $1.1M | $5.2M | $10.4M | |
| Total Assets | $2.9M | $2.0M | $2.0M | $12.2M | $17.0M | |
| Total Current Liabilities | $1.7M | $489.8K | $707.9K | $6.0M | $8.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $6.1M | |
| Total Liabilities | $1.8M | $1.9M | $2.2M | $7.5M | $16.3M | |
| Stockholders' Equity | $1.2M | $85.8K | -$177.4K | $4.7M | $686.9K | |
| Retained Earnings | -$17.2M | -$17.4M | -$19.2M | -$22.4M | -$29.2M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | -$1.4M | -$1.4M | -$2.6M | -$4.3M | |
| Capital Expenditure | $0.00 | -$44.3K | -$99.5K | -$153.0K | -$2.00 | |
| Free Cash Flow | -$1.2M | -$1.4M | -$1.5M | -$2.7M | -$4.3M | |
| Investing Cash Flow | -$17.7K | -$44.3K | -$99.5K | -$153.0K | -$139.3K | |
| Financing Cash Flow | $350.0K | $500.0K | $1.2M | $6.9M | $11.6M | |
| Issuance of Stock | $350.0K | $500.0K | $1.2M | $6.9M | $3.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $6.7M | |
| Stock Based Comp. | $1.9M | $640.3K | $352.8K | $419.2K | $0.00 | |
| Net Change in Cash | $2.1M | -$922.0K | -$308.4K | $4.2M | $7.1M |
Dilution Tracker
Shares Outstanding
30M
5-Year Share Growth
+4.3%
Stock Issuance (TTM)
$3.8M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 13.18 | 13.25 | 13.42 | 13.74 | 29.79 | |
| Change vs Prior % | — | 0.5% | 1.3% | 2.4% | 116.7% | |
| Stock Issuance | $350.0K | $500.0K | $1.2M | $6.9M | $3.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.9M | $640.3K | $352.8K | $419.2K | $0.00 |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| ROE % | -371.1% | -2672.6% | 996.7% | -68.2% | -280.4% | |
| ROA % | -147.1% | -113.8% | -86.3% | -26.3% | -49.8% | |
| ROIC % | -339.8% | -149.0% | -130.1% | -94.4% | -84.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 100.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 45.2% | 22.1% | -226.0% | |
| Net Income | 0.0% | 46.5% | 22.9% | -80.6% | |
| EPS (Diluted) | 0.0% | 48.5% | 23.5% | -76.9% | |
| Operating Cash Flow | 0.0% | -11.3% | 1.2% | -88.3% | |
| Free Cash Flow | 0.0% | -14.9% | -2.7% | -85.9% | |
| R&D Expense | 0.0% | 0.0% | 3179.4% | 8.0% | |
| SG&A Expense | 0.0% | -45.3% | -32.6% | 260.6% | |
| Total Assets | 0.0% | -30.9% | 1.8% | 493.6% | |
| Book Value / Share | 0.0% | -92.6% | -304.2% | 2679.7% | |
| Debt | 0.0% | -69.9% | 381.1% | -33.6% | |
| Diluted Shares | 0.0% | 0.5% | 1.3% | 2.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B411.12
10Y Low / Med / High11.55 / 79.84 / 1081.18
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.18
Cash / Share
$0.35
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| P/E Ratio | -21.21 | -41.18 | -53.85 | -17.13 | -32.53 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 79.84 | 1081.18 | -529.55 | 11.55 | 411.12 | |
| EV/EBITDA | -21.70 | -40.73 | -54.16 | -15.65 | -68.08 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
7.50
Safe
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $300.0K | $3.4M | $6.0M |
| Net Income | -$6.0M | -$5.8M | -$7.1M |
| EPS | $-0.44 | $-0.42 | $-0.52 |
| # Analysts (EPS) | 1 | 1 | 2 |